Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily immunosuppression after liver transplantation
2023-506601-19-00Phase 4Authorised
- Sponsor
- CHU de Limoges
- Start
- May 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus and mycophenolate mofetil in liver transplant (4 arms), sponsored by CHU de Limoges. Primary endpoint: Treatment failure at 6 or 18 months. Planned start May 2024; status: authorised.
02
Drugs
tacrolimusmycophenolate mofetil
03
Conditions
liver transplant
Beyond the preview
Go deeper on 2023-506601-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506601-19-00.